mTOR Inhibitors in the complex treatment of high-risk vascular malformations in children
Recent experimental and clinical studies demonstrated that mTOR receptor inhibitors can stop the progression of vascular malformations and significantly improve patients' quality of life. This is possible due to the interruption of the chain of phosphatidylinositol-3-kinase (PI3K) / AKT / mTOR...
Saved in:
Main Authors: | I.M. Benzar (Author), D.V. Zhumik (Author) |
---|---|
Format: | Book |
Published: |
Group of Companies Med Expert, LLC, Kyev, Ukraine,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Early Adjuvant Medication With the mTOR Inhibitor Sirolimus in a Preterm Neonate With Compressive Cystic Lymphatic Malformation
by: Marion Honnorat, et al.
Published: (2020) -
mTOR in Human Diseases
by: Dormond, Olivier
Published: (2019) -
Case Report: Tuberous sclerosis complex-associated hemihypertrophy successfully treated with mTOR inhibitor sirolimus
by: Konomi Shimoda, et al.
Published: (2024) -
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment
by: Xianbo Wu, et al.
Published: (2022) -
Management of mTOR inhibitors oral mucositis: current state of knowledge
by: Calvo Anne Sophie, et al.
Published: (2019)